"Reiteration of guidance may help provide some comfort most of this represents seasonality exaggerated by pandemic pressures," RBC Capital Markets analyst Brian Abrahams said in a research note. Gilead said the COVID-19 pandemic continued to hurt sales of HIV and hepatitis C drugs, due to fewer people going to doctors during the pandemic. It now expects a more gradual recovery in the market starting in the current quarter. "Our core business was impacted by COVID-19 more than we had expected," Chief Executive Daniel O'Day said during a conference call with investors.